William Messer

Associate Professor

Oregon Health & Science University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background The yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite its longstanding success, few studies have characterized the capacity of 17D-immune sera to neutralize wild-type (WT) yellow fever viruses (YFVs). Methods We use 17D and a panel of 13 WT YFVs that represent the known YFV genotypes and a unique cohort of 36 non-endemic vaccinees with diverse Orthoflavivirus infection histories to conduct focus neutralization tests to characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFV. Results We found significant variability in neutralization test titers and rates of seropositivity of 17D-immune sera across all viruses and specifically against South America-genotype I (SA-I) isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly greater potency against SA-I strains compared to sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity. Conclusions These results add significantly to what is known regarding the WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine design and deployment strategies.

Year:

2026

The yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite its longstanding success, few studies have characterized the capacity of 17D-immune sera to neutralize wild-type (WT) yellow fever viruses (YFVs). Using a panel of WT YFVs that represent the known YFV genotypes and a unique cohort of non-endemic vaccinees with diverse Orthoflavivirus infection histories, we extensively characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFV. We found significant variability in neutralization test (NT) titers and rates of seropositivity of 17D-immune sera against South America-genotype I (SA-I) isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly great potency against SA-I strains compared to sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity. These results add significantly to what is known regarding WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine strategies.

Year:

2025

Year:

2024

Hospitalized COVID-19 patients exhibit diverse immune responses during acute infection, which are associated with a wide range of clinical outcomes. However, understanding these immune heterogeneities and their links to various clinical complications, especially long COVID, remains a challenge. In this study, we performed unsupervised subtyping of longitudinal multi-omics immunophenotyping in over 1,000 hospitalized patients, identifying two critical subtypes linked to mortality or mechanical ventilation with prolonged hospital stay and three severe subtypes associated with timely acute recovery. We confirmed that unresolved systemic inflammation and T-cell dysfunctions were hallmarks of increased severity and further distinguished patients with similar acute respiratory severity by their distinct immune profiles, which correlated with differences in demographic and clinical complications. Notably, one critical subtype (SubF) was uniquely characterized by early excessive inflammation, insufficient anticoagulation, and fatty acid dysregulation, alongside higher incidences of hematologic, cardiac, and renal complications, and an elevated risk of long COVID. Among the severe subtypes, significant differences in viral clearance and early antiviral responses were observed, with one subtype (SubC) showing strong early T-cell cytotoxicity but a poor humoral response, slower viral clearance, and greater risks of chronic organ dysfunction and long COVID. These findings provide crucial insights into the complex and context-dependent nature of COVID-19 immune responses, highlighting the importance of personalized therapeutic strategies to improve both acute and long-term outcomes.

Year:

2024

Year:

2023

Year:

2023

Collaborators (15)

Hanno Steen

Professor

Harvard Medical School

UNITED STATES
View details

PENGHUA WANG

Associate Professor w/tenure

University of Connecticut Health Center

UNITED STATES
View details

Joann Diray Arce

Assistant Professor

Boston Children's Hospital

UNITED STATES
View details

Akiko Iwasaki

Professor

Yale University School of Medicine

UNITED STATES
View details

Fikadu Tafesse

Professor and Chair

Oregon Health & Science University

UNITED STATES
View details

Dina Fonseca

Professor, Department Chair

Rutgers University

UNITED STATES
View details

Michael Wilson

Professor

University of California, San Francisco

UNITED STATES
View details

Cole Maguire

University of Texas at Austin

UNITED STATES
View details

Harm van Bakel

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Al Ozonoff

Associate Professor

Harvard University

UNITED STATES
View details

Harlan Krumholz

Professor of Medicine

Yale University

UNITED STATES
View details

Savannah McBride

Columbia University

UNITED STATES
View details

Lauren Ehrlich

Professor

University of Texas at Austin

UNITED STATES
View details

Esther Annan

Cornell University

UNITED STATES
View details

Juergen Pilz

Head of Department/ University Professor

Alpen-Adria-Universität Klagenfurt

AUSTRIA
View details